Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics, and Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven biotechnology company, have entered a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

Under the collaboration agreement, the parties will combine Harbour BioMed’s technology platform, proprietary dataset and expertise in antibody development with Insilico’s advanced capabilities in designing integrated AI-driven drug discovery and development platforms to jointly develop a next-generation AI-powered antibody application. Additionally, the two companies will collaborate on early-stage drug discovery programs targeting novel, specific antibodies, leveraging Insilico’s AI expertise and Harbour BioMed’s wet lab capabilities. These efforts aim to deliver innovative therapeutic solutions for the unmet medical needs of immunology, oncology, and neuroscience.

Harbour BioMed, with its advanced technology platform, proprietary dataset, and expertise, has built a strong foundation in antibody discovery and development. Its Harbour Mice platform generates fully human monoclonal antibodies in conventional and heavy chain-only formats, eliminating the need for additional engineering. HCAb technology produces unique, half-size antibodies with significant advantages for next-generation therapies. With a clinically validated platform, Harbour BioMed has applied its technology in over 250 drug discovery programs across various therapeutic areas, establishing itself as a leader in biotherapeutics.

Insilico’s proprietary AI platform has significantly reduced cost and improved efficiency in early small molecule drug discovery. Since 2021, the company has established a pipeline of 30 assets powered by Pharma.AI, with 10 receiving IND clearance. In July 2024, Insilico introduced Generative Biologics, an AI-powered tool for de novo protein engineering to accelerate biologics development. The company plans to refine and advance the application through real-world case studies and ongoing enhancements.

“We are excited to collaborate with Insilico, a pioneer and leading advocate in AI-driven drug discovery and development, to integrate AI technologies with our industry-leading technology platform and proven expertise in antibody discovery and development,” said Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed. “By combining our validated Harbour Mice platform with advanced generative AI approaches, we aim to further streamline antibody discovery, enhance candidate selection, and ultimately bring innovative therapies to patients more efficiently.”

“By combining advanced machine learning models with biological expertise, AI platforms are transforming antibody discovery and engineering, enabling the prediction of antibody structures, identification of binding sites, and design of candidates with enhanced specificity, efficacy, and safety,” said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. “Together, we aim to build the next generation AI-driven antibody platforms and deliver breakthrough antibody therapies to address critical healthcare needs.”